The small-cap biopharmaceutical stock featured in today’s article is a Buy according to the consensus among analysts, who see upside potential of nearly 200% from current levels. For more on this small-cap biopharma stock – including recent trade information, estimates and forecasts, and major shareholders – CLICK HERE.
Analysts Say This Small-Cap Biopharmaceutical Stock Is A Buy
- by Alex Clarke
Tags:Biotech StocksInvestingInvestmentsShareholdersSharesSmall-Cap Biopharma StockSmall-Cap Biopharmaceutical StocksSmall-Cap InvestmentsStock MarketStocksTradesUpside Potential